This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Wed, March 18, 2026 astatine 10:57 AM CDT 4 min read

On February 17, 2026, Superstring Capital Management disclosed a caller presumption successful Axsome Therapeutics (NASDAQ:AXSM), acquiring 37,433 shares worthy $6.84 cardinal successful the 4th quarter.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Superstring Capital Management initiated a caller presumption successful Axsome Therapeutics during the 4th fourth of 2025. The money bought 37,433 shares worthy $6.84 cardinal astatine quarter’s end.

This caller presumption represents astir 4% of Superstring Capital Management LP’s 13F assets nether absorption astatine quarter’s end.
Top holdings aft the filing:
- NASDAQ: CDTX: $18.80 cardinal (10.1% of AUM)
- NASDAQ: TERN: $17.93 cardinal (9.6% of AUM)
- NASDAQ: URGN: $16.82 cardinal (9.0% of AUM)
- NASDAQ: COGT: $13.01 cardinal (7.0% of AUM)
- NASDAQ: DVAX: $8.08 cardinal (4.3% of AUM)
As of Wednesday, shares of Axsome Therapeutics were priced astatine $158.40, up 27% implicit the past twelvemonth and good outperforming the S&P 500’s astir 19% summation successful the aforesaid period.

Metric

Value

Revenue (TTM)	$638.5 million
Net Income (TTM)	($183.2 million)
Market Capitalization	$8.1 billion
Price (as of Wednesday)	$158.40

Axsome Therapeutics develops and commercializes caller therapies targeting cardinal tense strategy (CNS) disorders, with a pipeline including AXS-05 for large depressive upset and Alzheimer’s illness agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.
The company’s concern exemplary centers connected proprietary cause development, advancing candidates done objective trials and regulatory approval, and generating gross from merchandise income and imaginable licensing agreements.
Axsome chiefly serves healthcare providers and patients successful the United States, focusing connected unmet aesculapian needs wrong neurology and psychiatry.

Axsome Therapeutics is simply a clinical-stage biopharmaceutical institution specializing successful CNS upset therapeutics. The institution differentiates itself done a robust late-stage pipeline and a absorption connected addressing large gaps successful neuropsychiatric and neurological care. This strategy positions Axsome to seizure important marketplace opportunities arsenic its therapies beforehand toward regulatory support and commercialization.

This determination is absorbing due to the fact that it shifts vulnerability toward a institution that is already generating gross and not conscionable chasing objective milestones, adding a antithetic hazard illustration to a portfolio dominated by earlier-stage biotech bets.

Axsome already has commercialized products connected the market, including therapies for depression, migraine, and slumber disorders, which assistance money its pipeline and trim near-term financing risk. That stands successful opposition to different positions that are inactive afloat babelike connected proceedings outcomes.

At the aforesaid time, maturation inactive hinges connected execution. The institution precocious initiated a Phase 3 proceedings for solriamfetol targeting large depressive upset with excessive daytime sleepiness, a conception affecting millions of patients with nary approved treatments today. That proceedings adds different imaginable statement enlargement accidental connected apical of an already wide CNS pipeline.

With the steadfast advancing its pipeline and posting $638.5 cardinal of full-year revenue, up 66% from 2024, it’s nary astonishment that a money similar Superstring would measurement successful with bullishness.

Read Entire Article